Michel Farnier Articles
PCSK9 Clinical trials: What’s new?
Dr Michel Farnier MD PhD Clinician based at Point Medical, Dijon, France
read more »Posted on 16 July 2015 |
Posted by Michel Farnier | Posted in Webcasts,
2nd Closed Scientific Expert Meeting of the Editorial Board,
2nd Closed Expert Meeting of the Editorial Board 2015
ACC 2015 ODYSSEY CHOICE: Flexibility in alirocumab dosing
Results from the ODYSSEY CHOICE studies indicate flexibility in dosing with alirocumab, with 4-weekly regimens shown to be effective and well tolerated, according to Dr Michel Farnier, Point Medical, Dijon, France. Many patients at moderate to high cardiovascular (CV) risk and with poorly controlled hypercholesterolaemia…
read more »Posted on 18 March 2015 |
Posted by Michel Farnier | Posted in News,
64th Annual Scientific Session of the American College of Cardiology 2015
ODYSSEY FHI FHII
Fewer than 80% of familial hypercholesterolaemia (FH) patients achieved an LDL-C level of
read more »Posted on 2 September 2014 |
Posted by Michel Farnier | Posted in News,
Videos,
European Society of Cardiology Congress 2014
PCSK9: From discovery to therapeutic applications
PUBMED abstract: http://www.ncbi.nlm.nih.gov/pubmed/24373748
read more »
